Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization

Published:September 16, 2019DOI:https://doi.org/10.1016/j.ijrobp.2019.09.006

      Purpose

      With increasing use of radiation for hepatocellular carcinoma (HCC) through transarterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT), there is concern for increased radiation-related complications when using SBRT after TARE. This study compares safety of SBRT after segmental TARE versus transarterial chemoembolization (TACE).

      Methods and Materials

      A retrospective review identified patients receiving SBRT after TACE or TARE for HCC from 2011 to 2017. TARE was delivered subselectively to individual segments using yttrium-90 with Theraspheres. Patients were assessed over time for Child-Turcott-Pugh (CTP)/albumin-bilirubin (ALBI) scores, and Common Terminology Criteria for Adverse Events version 4.0 grade ≥3 events. Linear mixed models were used to examine the trend of CTP and ALBI over time and compare groups. Secondary endpoints were objective response rate via modified Response Evaluation Criteria in Solid Tumors (RECIST), local control, and overall survival.

      Results

      Ninety-nine patients met criteria with median follow-up of 9.8 months (range, 0.9-47): 31 had SBRT after segmental TARE and 68 patients post-TACE. The groups were well balanced with regard to etiology of HCC, baseline CTP and ALBI scores, and SBRT dose, but there were significant differences in baseline Eastern Cooperative Oncology Group performance status, Barcelona Clinic Liver Cancer staging, and median follow-up. There was a significant increase in post-SBRT CTP and ALBI scores (P < .0001) for both groups. However, there was no significant difference in rise in CTP (P = .11) or ALBI score (P = .82) over time between SBRT post-TACE versus post–segmental TARE. There was no significant increase in ≥grade 3 toxicity postsegmental TARE. There was also no significant difference in local controls (P = 1.0) and overall survival (P = .26) between cohorts, but objective response rate was worse post-TARE.

      Conclusions

      SBRT after segmental TARE with Theraspheres appears to have acceptable tolerability and is effective compared with SBRT after TACE. Longer follow-up with larger numbers is needed to verify these data.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • et al.
        Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.
        Int J Can. 2015; 136: E359-E386
        • Petrick J.L.
        • Kelly S.P.
        • Altekruse S.F.
        • et al.
        Future of hepatocellular carcinoma incidence in the United States forecast through 2030.
        J Clin Oncol. 2016; 34: 1787-1794
        • Bruix J.
        • Sherman M.
        Management of hepatocellular carcinoma: An update.
        Hepatology. 2011; 53: 1020-1022
        • Delis S.G.
        • Dervenis C.
        Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease.
        World J Gastroenterol. 2008; 14: 3452-3460
        • Llovet J.M.
        • Burroughs A.
        • Bruix J.
        Hepatocellular carcinoma.
        Lancet. 2003; 362: 1907-1917
        • Llovet J.M.
        • Bru C.
        • Bruix J.
        Prognosis of hepatocellular carcinoma: The BCLC staging classification.
        Semin Liver Dis. 1999; 19: 329-338
        • Lencioni R.
        • Petruzzi P.
        • Crocetti L.
        Chemoembolization of hepatocellular carcinoma.
        Semin Intervent Radiol. 2013; 30: 3-11
        • Bujold A.
        • Massey C.A.
        • Kim J.J.
        • et al.
        Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.
        J Clin Oncol. 2013; 31: 1631-1639
        • Huertas A.
        • Baumann A.S.
        • Saunier-Kubs F.
        • et al.
        Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma.
        Radiother Oncol. 2015; 115: 211-216
        • Gkika E.
        • Schultheiss M.
        • Bettinger D.
        • et al.
        Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
        Radiat Oncol. 2017; 12: 116
        • Yamashita H.
        • Onishi H.
        • Murakami N.
        • et al.
        Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma.
        J Radiat Res. 2015; 56: 561-567
        • Mendez Romero A.
        • Wunderink W.
        • van Os R.M.
        • et al.
        Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors.
        Int J Radiat Oncol Biol Phys. 2008; 70: 1447-1452
        • Tse R.V.
        • Hawkins M.
        • Lockwood G.
        • et al.
        Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
        J Clin Oncol. 2008; 26: 657-664
        • Sterzing F.
        • Brunner T.B.
        • Ernst I.
        • et al.
        Stereotactic body radiotherapy for liver tumors: Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy.
        Strahlenther Onkol. 2014; 190: 872-881
        • Jia Z.
        • Jiang G.
        • Tian F.
        • et al.
        A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
        Saudi J Gastroenterol. 2016; 22: 353-359
        • Ricke J.
        • Bulla K.
        • Kolligs F.
        • et al.
        Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC.
        Liver Int. 2015; 35: 620-626
        • Huo Y.R.
        • Eslick G.D.
        Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and meta-analysis.
        JAMA Oncol. 2015; 1: 756-765
      1. Kimura T, Aikata H, Doi Y, et al. Comparison of stereotactic body radiation therapy combined with or without transcatheter arterial chemoembolization for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Technol Cancer Res Treat 2108;17:1533033818783450.

        • Kalogeridi M.A.
        • Zygogianni A.
        • Kyrgias G.
        • et al.
        Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review.
        World J Hepatol. 2015; 7: 101-112
        • Pan C.C.
        • Kavanagh B.D.
        • Dawson L.A.
        • et al.
        Radiation-associated liver injury.
        Int J Radiat Oncol Biol Phys. 2010; 76: S94-S100
        • Velec M.
        • Haddad C.R.
        • Craig T.
        • et al.
        Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma.
        Int J Radiat Oncol Biol Phys. 2017; 97: 939-946
        • Lam M.G.
        • Abdelmaksoud M.H.
        • Chang D.T.
        • et al.
        Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy.
        Int J Radiat Oncol Biol Phys. 2013; 87: 323-329
        • Salem R.
        • Lewandowski R.J.
        • Mulcahy M.F.
        • et al.
        Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes.
        Gastroenterology. 2010; 138: 52-64
        • Salem R.
        • Thurston K.G.
        Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.
        J Vasc Interv Radiol. 2006; 17: 1251-1278
        • Lewandowski R.J.
        • Sato K.T.
        • Atassi B.
        • et al.
        Radioembolization with 90Y microspheres: Angiographic and technical considerations.
        Cardiovasc Intervent Radiol. 2007; 30: 571-592
        • Siegel J.A.
        • Thomas S.R.
        • Stubbs J.B.
        • et al.
        MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.
        J Nucl Med. 1999; 40: 37s-61s
        • Rim C.H.
        • Seong J.
        Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines.
        Radiat Oncol J. 2016; 34: 160-167
        • Tanimoto K.
        • Rusu I.
        • Martin B.
        • et al.
        Role of stereotactic body radiation therapy in patients with hepatocellular carcinoma extensively pretreated with transarterial chemoembolization or yttrium-90.
        J Clin Oncol. 2018; 36 (233-233)
        • Wahl D.R.
        • Stenmark M.H.
        • Tao Y.
        • et al.
        Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma.
        J Clin Oncol. 2016; 34: 452-459
        • Weiner A.A.
        • Olsen J.
        • Ma D.
        • et al.
        Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study.
        Radiother Oncol. 2016; 121: 79-85
        • Toesca D.A.
        • Osmundson E.C.
        • Eyben R.V.
        • et al.
        Central liver toxicity after SBRT: An expanded analysis and predictive nomogram.
        Radiother Oncol. 2017; 122: 130-136
        • Eriguchi T.
        • Takeda A.
        • Sanuki N.
        • et al.
        Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
        Int J Radiat Oncol Biol Phys. 2013; 85: 1006-1011
        • Mendiratta-Lala M.
        • Masch W.
        • Shankar P.R.
        • et al.
        Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: Long term imaging follow-up.
        Int J Radiat Oncol Biol Phys. 2019; 103: 169-179

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.